Skip to main content

Advertisement

SpringerLink
Log in

Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma

  • Letter to the Editor
  • Published:
World Journal of Urology Aims and scope Submit manuscript

The Original Article was published on 20 May 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

References

  1. Yanagisawa T, Kawada T, Quhal F et al (2023) Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol. https://doi.org/10.1007/s00345-023-04412-0

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yuan Y, Liu L, Chen H et al (2016) Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 29:711–722. https://doi.org/10.1016/j.ccell.2016.04.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Song Y, Qin C, Zhang C et al (2023) GNRH family genes contributed to gender-specific disparity of bladder cancer prognosis through exerting opposite regulatory roles between males and females. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-023-04640-2

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zhang X, Cheng L, Gao C et al (2023) Androgen signaling contributes to sex differences in cancer by inhibiting NF-κB activation in T cells and suppressing antitumor immunity. Cancer Res 83:906–921. https://doi.org/10.1158/0008-5472.CAN-22-2405

    Article  CAS  PubMed  Google Scholar 

  5. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2022) Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane 2022. http://www.training.cochrane.org/handbook. Accessed Feb 2022

Download references

Funding

This study was supported by National Key Research and Development Program of China (2018YFA0902802).

Author information

Author notes

  1. Yuxuan Song and Yun Peng contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, Peking University People’s Hospital, Beijing, 100044, China

    Yuxuan Song, Yun Peng & Caipeng Qin

Authors
  1. Yuxuan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caipeng Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YS: project development, literature collection, and manuscript writing. YP: project development, literature collection, and manuscript writing. CQ: project development and manuscript writing.

Corresponding author

Correspondence to Caipeng Qin.

Ethics declarations

Conflict of interest

The author declares that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

All the authors consent for the publication of the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, Y., Peng, Y. & Qin, C. Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma. World J Urol 41, 2301–2302 (2023). https://doi.org/10.1007/s00345-023-04497-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04497-7

Search

Navigation